Project A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202)…

Basic data

Title:
A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy
Duration:
01/10/2015 to 30/09/2018
Abstract / short description:
A randomised, double blind phase II trial to determine efficacy, safety and immunogenicity of BI 1361849 (CV9202) maintenance vaccination therapy versus placebo given intradermally in newly diagnosed patients with inoperable locally advanced NSCLC after definitive concurrent chemoradiation therapy
Keywords:
clinical trial
klinische Studie

Staff

Managers

Faculty of Medicine
University of Tübingen

Contact persons

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Diagnostic and Interventional Radiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Ingelheim am Rhein, Rheinland-Pfalz, Germany
Help

will be deleted permanently. This cannot be undone.